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As part of the innate immune system, the Toll-like receptors (TLRs) represent 
key players in the first line of defense against invading foreign pathogens, and 
are also major targets for therapeutic immunomodulation. TLRs are type I 
transmembrane proteins composed of an ectodomain responsible for ligand 
binding, a single-pass transmembrane domain, and a cytoplasmic 
Toll/Interleukin-1 receptor (TIR) signaling domain. The ectodomains of TLRs 
are specialized for recognizing a wide variety of pathogen-associated molecular 
patterns, ranging from lipids and lipopeptides to proteins and nucleic acid 
fragments. The members of the TLR family are highly conserved and their 
ectodomains are composed of characteristic, solenoidal leucine-rich repeats 
(LRRs). Upon ligand binding, these rigid LRR scaffolds dimerize (or re-organize 
in the case of pre-formed dimers) to bring together their carboxy-terminal 
transmembrane and TIR domains. The latter are proposed to act as a platform 
for recruitment of adaptor proteins and formation of higher-order complexes, 
resulting in propagation of downstream signaling cascades. In this review, we 
discuss the protein-protein interactions critical for formation and stability of 
productive, ligand-bound TLR complexes. In particular, we focus on the large 
body of high-resolution crystallographic data now available for the ectodomains 
of homo- and heterodimeric TLR complexes, as well as inhibitory TLR-like 
receptors, and also consider computational approaches that can facilitate our 
understanding of the ligand-induced conformational changes associated with 
TLR function. We also briefly consider what is known about the protein-protein 
interactions involved in both TLR transmembrane domain assembly and TIR-
mediated signaling complex formation in light of recent structural and 
biochemical data.  
 
INTRODUCTION 
The mammalian body is consistently exposed to foreign pathogens. In order to 
defend itself, the innate immune system provides a rapid first response to such 
attacks. This is achieved via recognition of various evolutionarily conserved 
“patterns” associated with foreign pathogenic molecules referred to as pathogen-
associated molecular patterns (PAMPs) [1,2]. PAMPs are defined as being 
uniform within their pathogen class (i.e. virus vs bacteria vs fungi), functionally 
essential, and distinguishable from the host. Janeway first hypothesized in 1989 
the existence of a class of receptors termed pattern recognition receptors (PRRs) 
in the innate immune system for PAMP recognition [3]. The PRRs would induce a 
signal to the host alerting it to the presence of foreign pathogens, initiating a pro-
inflammatory response [1-3] that includes the expression of a large number of 
molecules including cytokines, chemokines, cell adhesion molecules and other 
immune receptors [1]. In 1997 Janeway further identified the family of PRRs 
called the Toll-like receptors (TLRs) [4], which remain the most extensively 
studied PRRs today. The importance of TLRs is highlighted by the various 
infectious and noninfectious disease states that can result from their 
dysregulation, and by their consequent extensive therapeutic targeting [5-9]. 
 
Ten functional members of the TLR family are found in the human genome (Fig 
1) and each member identifies distinct PAMPs. TLRs may be distinguished by 















molecules, versus those that are activated by foreign, processed nucleic acids 
within endosomal compartments (Table 1). The set of human TLRs recognize a 
broad range of ligands, including both small molecules, and large polar or 
nonpolar macromolecules (Table 1). TLR1, 2 and 6 respond to lipoproteins, 
lipopeptides and Gram-positive bacterial peptidoglycans [10,11]. TLR4 is 
activated mainly through lipopolysaccharide from the outer membranes of 
Gram-negative bacteria [12]. TLR5 is stimulated by flagellin, a protein involved 
in motility in many bacteria. In contrast, TLR3, 7, 8 and 9 are activated by viral 
pathogenic molecules [13-16], namely: TLR3, double stranded RNA [17] 
associated with many viruses; TLR7 and 8, single stranded RNA present in 
viruses such as Ebola [14-16,18]; TLR9, CpG-rich DNA, a form of DNA prevalent 
in viral and bacterial genomes [19]. 
 
All TLRs are type I transmembrane proteins. Each TLR is composed of an 
ectodomain responsible for PAMP recognition, a helical transmembrane (TM) 
domain, and a cytoplasmic Toll/Interleukin-1 receptor (TIR) domain [3,4,20-23]. 
All TLRs dimerize (TLR1-6) - or reorganize in the case of pre-formed inactive 
dimeric complexes (TLR7-9) - upon binding of agonistic ligands by the 
ectodomains. Such ligands cause dimerization by facilitating the formation of 
stable protein-protein interfaces between TLR chains, either directly, or via co-
receptor proteins in the case of TLR4. Dimerization is proposed to initiate a 
signal, either through homodimerization (TLR 3, 4, 5, 8 & 9) or 
heterodimerization (TLR 1, 2, 6 & 10) [3,4,20-23]. The consequent 
rearrangements resulting from formation of the dimeric ectodomain complex are 
transferred via an ill-defined mechanism to the now adjacent carboxy-terminal 
juxtamembrane and TM helices, inducing dimerization of the cytoplasmic TIR 
domains. These are then proposed to act as a scaffold for the recruitment of 
adaptor proteins that also contain TIR domains, leading to the formation of 
higher-order complexes and subsequent transduction of downstream signaling 
[3,4,10,20-24].  
 
The general function of TLRs is now well understood, with both physiological 
and non-physiological ligands identified for most, and the structural basis for 
ligand recognition and activation has been intensively studied for a number of 
these TLRs. Currently, high-resolution ligand-bound structures are available for 
multiple TLRs derived either from mammalian species or that are sufficiently 
homologous to the equivalent human TLR to derive a structural basis for 
function. In this review, we focus on the atomic scale protein-protein 
interactions that are believed to be key to TLR function. Consistent with the 
varying ligand specificities and cellular localization across the TLR family, each 
member exhibits a broad range of stabilizing dimerization interfaces, both in 
terms of polarity or hydrophobicity and surface area (Table 1). Crystallographic 
studies of TLR-ligand complexes to date have utilized truncated receptor 
structures, encompassing only the ectodomain involved in ligand-recognition. 
Thus, we necessarily focus on these associated protein-protein interactions, and 
the available information concerning the agonist-induced functional 
conformational changes and/or dynamics. We also describe those involved in the 
case of the unique TLR-like RP105 protein, which does not contain intracellular 















protein interactions with the TLR4 complex. Whilst far less is known about the 
interactions involved in the TM and intracellular domains, we conclude the 
review by briefly highlighting recent progress towards filling this gap in our 
knowledge, via a combination of biochemical, structural, and computational 
approaches. 
 
TOLL-LIKE RECEPTOR ECTODOMAINS 
The ectodomain is highly conserved across members of the TLR family, and 
across species [25]. TLRs are members of the leucine rich repeats (LRRs) class of 
proteins [26]. This prominent class is present in viruses and bacteria, as well as 
eukaryotic cells [27]. LRR-containing proteins play roles in a wide variety of 
functions, including as hormone receptors, immune receptors, tyrosine kinase 
receptors, and enzymes [27,28].  Despite their broad functional capacity, a 
general observation is that all LRRs tend to be involved in protein-protein 
interactions [27,29,30]. Whilst LRRs vary greatly in the number of repeated 
“LRR” segments and how long these segments are (~20-30 residues), the core 
LRR sequence motif is highly conserved, consisting of the following sequence: 
LxxLxLxxN (where L=Val/Leu/Ile,  N= Asn/Thr/Ser/Cys, and x= any amino acid) 
(21, 22, 25). These repeating motifs within LRR proteins fold into bent solenoidal 
structures, made up of parallel β-sheets at the concave inner face, with each 
strand corresponding to one LRR motif, and the conserved leucine sidechains 
forming the hydrophobic core. The residues in the convex portion tends to adopt 
a more diverse range of secondary structural motifs including helices and loops 
[31]. In the case of the conserved asparagine residues, these help to form a 
continuous hydrogen-bonding network with backbone carbonyls of adjacent 
LRRs.  The variable “x” residues are exposed to solvent and can play roles in 
ligand recognition. Finally, the hydrophobic core of the LRR modules at the 
amino- and carboxy-termini need to be buried from solvent for stability, and 
hence require additional disulfide bridge-containing capping modules, termed 
the LRRNT and LRRCT,  respectively. Outside of these common features, TLRs 
display a number of unusual properties compared to typical LRR proteins. Thus, 
in contrast with most LRR ligand interaction sites, the binding sites for ligands in 
TLRs tend to be found on the convex sides of their solenoidal structures. Certain 
LRR segments in TLRs deviate from the consensus motif, resulting in specialized 
surfaces or pockets for ligand; in particular, TLR1, TLR2, TLR4 and TLR6 lack 
asparagine networks in their central region, enabling structural distortions that 
facilitate interactions with hydrophobic ligands including lipids and lipopeptides 
[20-23,32]. 
 
Upon TLR dimerization, there is very little change in the secondary structure or 
conformation of the individual chains, demonstrating the rigidity of the LRR 
motifs [31]. Thus, the overall shape of each ligand-bound ectodomain TLR dimer 
is strikingly similar, forming a characteristic “m” shaped structure with the 
carboxy-termini tails in the center of the complex, enabling juxtaposition of the 
intracellular TIR domains.  On the other hand, whilst TLR1, TLR2, TLR6 and 
TLR10 are similar in size, with 20 LRR repeats, TLR3, TLR4 and TLR5 have 25, 
23 and 22 LRRs respectively, whilst TLR7, TLR8 and TLR9 are bigger still with 
27 LRRs each [33]. The number of LRRs involved in each TLR-TLR interface 















the size of the proteins (Table 1). The largest TLR ectodomains, TLR8 and TLR9 
(and probably TLR7), utilize 9-10 LRRs at their dimer interface. The smaller 
ectodomains of TLR1, TLR2 and TLR6 (and probably TLR10) involve 4-5 LRRs at 
the dimer interface, whilst four LRRs are involved in the dimer interface of TLR4, 
and just 1-2 LRRs in the case of TLR3 and TLR5.  
 
In the following section, we focus on the ectodomains of individual TLR homo- 
and hetero-dimers, and highlight key features of their associated protein-protein 
interactions that facilitate ligand recognition, dimerization, and downstream 
signaling.  
 
TLR1-TLR2 and TLR2-TLR6 Heterodimers 
TLR2 is a unique member of the TLR family in that it can dimerize with both 
TLR1 and TLR6; the resultant heterodimers are respectively specific for either 
tri-acylated or di-acylated bacterial lipopeptides and lipoproteins. The tri-
acylated lipopeptides are often associated with Gram negative bacteria 
[10,24,34,35], whereas their di-acylated counterparts [11] are predominantly 
found in Gram positive bacteria. There is significant heterogeneity in the 
structure and length of these lipopeptides in vivo. The structural basis for ligand 
recognition has been facilitated by the use of synthetic lipopeptides that mimic 
their bacterial counterparts, such as di-acylated Pam2CSK4 and tri-acylated 
Pam3CSK4. 
 
The crystal structure of human TLR2-TLR1 heterodimers bound to Pam3CSK4 
revealed that two acyl chains insert into the internal binding pocket on TLR2, a 
crevice formed between LRR11 and LRR12, extending internally to LRR9, whilst 
the final acyl chain inserts into a smaller binding channel present in the same 
region of TLR1. The ligand essentially bridges the two proteins, creating a 
coherent dimer interface [10]. This interface is stabilized through a hydrophobic 
core at the center, surrounded by hydrophilic residues forming hydrogen bonds 
and ionic interactions. The hydrophobic “patch” is composed of P315’, Y320’, 
V311’, V339’ and L359’ on TLR1 (where an apostrophe corresponds to TLR1) 
and Y323, L324, F322, P352, Y376, L350, F349, L371 and V373 on TLR2 [10]. 
Polymorphic variants of TLR1 without P315’ present in the interfacial 
hydrophobic core exhibit inhibited signaling behavior [36]. The hydrophilic 
region bordering the hydrophobic patch forms hydrogen bonds including K385’-
N345, T361’/T363’-K347, R337’-E375, and Q383’-H398, and ionic interactions 
are formed via E321’-H318/R321, E366’-R321, K385’-E369, R337’-E374, and 
D310’-K378 [10]. These regions are highly conserved across species, consistent 
with an identity between mouse and human sequences of 73% and 68% for 
TLR1 and TLR2, respectively [10]. Minor differences in sequence account for 
some variations in specificity between species. For instance, mouse TLR2 has a 
more compact binding pocket than the human equivalent [37], whilst the equine 
TLR1/TLR2 heterodimer has different affinity to Pam3CSK4 than the human 
dimer [38]. The peptide portion of the lipopeptide forms additional hydrogen 
bonds with the TLR chains to stabilize the bound conformation [10].  
 
TLR1 and TLR6 are highly homologous, sharing 56% sequence identity in mice 















lead to a change in specificity, though they still activate the same pathway 
[11,39]. Unlike the dimerization interface in the TLR1-TLR2 complex that is 
mediated by the binding cavities present between LRR9-12 on TLR1, the crystal 
structure of mouse TLR2-TLR6 in the presence of Pam2CSK4 revealed that 
dimerization is mediated by the surface exposed amino acids between LRR11-14 
(Fig 1B). In the latter complex, TLR2 still binds the two acyl tails within the 
internal binding cavity between LRR11 and LRR12 [11]. However, in TLR6, 
differences in the sequence compared to TLR1 results in a structural change such 
that F319’, L324’ and Y325’ move into the acyl chain binding channel present in 
TLR1, and effectively truncate it [11]. Much like TLR1-TLR2, the TLR2-TLR6 
interface is composed of a central hydrophobic core surrounded by hydrophilic 
residues that form hydrogen bonds and ionic interactions. Residues including 
F317’, L318’, Y325’, P342’, I344’, V347’ and V364’ constitute the hydrophobic 
“patch” on TLR6, highly conserved between species, and interact with F322, 
Y323, L324, F349, L350, L371, V373 and Y376 on TLR2. Hydrogen bonds formed 
at this interface include N314’-E375, P342’-Y376, Q362’-R400 and T366’-K347, 
along with salt bridges including H311’-E375, K313’-E375, D340’-R400/R404, 
D367’-H318/K347 and K390’-E369 [11]; unsurprisingly, many of the interacting 
residues from TLR2 are also involved in the TLR1 complex. Hydrogen bonds 
between ligand and loops of LRR11 also contribute to the stability of the complex 
by bridging TLR2 and TLR6, locking the conformation of the residues within the 
hydrophobic core into position [11]. Despite the reduced number of internalized 
acyl tails at the dimer interface, stable heterodimers form between TLR2 and 
TLR6 suggesting that the additional protein-protein interactions compensate for 
the reduction in ligand-protein interactions. This is in accordance with the 
observation that there is an 80% increase in the size of the hydrophobic “patch” 
of TLR6 compared to TLR1 [11].  
 
TLR10 Heterodimer 
TLR10 is believed to form heterodimers with TLR2 in a similar mode to TLR1, as 
TLR10 exhibits conservation of key residues at the dimerization interface and a 
lipopeptide binding channel, though lipopeptide binding has not yet been shown 
to induce signaling [40]. No data is so far available to confirm a precise agonist 
for TLR10, and no crystal structure is available for the ectodomain, though it has 
been shown to be involved in the response to viral infections, particularly 
influenza A [41]. Homology modeling studies indicated that like TLR1-TLR2, the 
TLR10-TLR2 complex is likely to have a large hydrophobic core surrounded by 
hydrophilic residues stabilizing the dimer interface [40].  The residues predicted 
to be in the hydrophobic core are L342’, Y320’, Y313’, V311’, P339’ and I359’ on 
TLR10, and Y323, L324, F322, P352, Y376, L350, F349, L371 and V373 on TLR2. 
This hydrophobic core resembles that of TLR1-TLR2 with residues being 
conserved (Y320 and V311) or conservatively preserved (L359/I359’ and 
V339/P339’). Hydrogen bonds stabilizing the interface may include: K383’-
E369/N345, E385’-N345, T361’-K347, E363’-K347, Q337’-E375 and N357’-
H398. In this region, a number of residues are conserved between TLR1 and 
TLR10 (K385/K383’ or E385’, T361/T361’, T363/E363’, R337/Q337’) [40]. 
Finally, ionic interactions at the interface are predicted to form between E363’-
H318/R321/K347, D317’-R321, D362’-K347, E385’-K347, K383’-E369, R310’-















conserved in this region [40]. Mutational studies performed at the hydrophobic 
core of TLR10 revealed that substitution of T320’, P339’ or I359’ with polar or 
charged residues dramatically reduces the binding of Pam3CSK4, which is 
capable of binding to TLR10 but not activating it [40]. Whilst TLR1 still retains 
most of its function in a Y320 mutant, the same mutation in TLR10 leads to a 
significant loss of binding ability. These mutational studies suggest that though 
similar in overall structure, TLR10 has subtle differences at its dimer interface 
that are likely to be the root of the difference in specificity between TLR1 and 
TLR10 [40]. Until a crystal structure is available and a TLR10 agonist identified, 
these results remain to be verified. 
 
TLR5 Homodimer 
TLR5 is activated by monomeric flagellin, a part of the tail-like portion of the 
protein flagellum that is responsible for bacterial motility [42]. There is still no 
crystal structure for mammalian TLR5, but a structure for zebrafish TLR5 as part 
of a  variable lymphocyte receptor (VLR) hybrid has been determined (Fig 1E). In 
addition, an electron microscopy structure was solved at 26 Å resolution for full 
length human TLR5 [43]. These studies revealed that TLR5 forms an asymmetric 
homodimer via ectodomain interactions [42-46]. It is also suspected that TLR5 
may dimerize in the absence of ligand [44], though conflicting structural 
evidence suggests that TLR5 may first heterodimerize with flagellin before 
forming the TLR homodimeric complex [43]. TLR5 contains glycosylation sites 
on its surface but retains a glycosylation free face where the TLR5-TLR5 dimer 
interface is located, along with the ligand binding site. The primary ligand 
binding site is located on the amino-terminal portion of TLR5 between LRRNT-
LRR10, and is split into two interfaces, A and B. Interface A is present between 
the concave and ascending region of the glycosylation-free face of LRRNT-LRR6, 
while interface B is present on the ascending glycosylation free face between 
LRR7 to LRR10. The secondary interface contains the dimerization interface of 
TLR5-TLR5, as well as a secondary ligand-binding interface for flagellin with the 
alternate TLR5 [43].  The secondary dimerization interface is maintained 
through hydrophobic interactions between three hydrophobic residues in the 
zebrafish structure, namely F273, F351 and H375. These residues are highly 
conserved across species, with the only sequence difference being the 
replacement of H375 by leucine in human, bovine, mouse, and chicken. There are 
also two sets of hydrogen bonds stabilising the interface, which are formed 
between R377-N350 and R377-Y373 [43]. Once a crystal structure is solved for 
human TLR5, these observations may be further verified. 
 
TLR3 Homodimer 
TLR3 is found in endosomes and dimerizes upon exposure to dsRNA molecules, 
which are PAMPs associated with a diverse range of viruses. Like TLR5, it 
maintains one glycosylation-free face where ligand binding occurs and where the 
dimerization interface is present [13,17] (Fig 1C). The electrostatic binding 
surface of TLR3 is basic, consistent with the overwhelmingly negatively charged 
nature of dsRNA, and includes two basic “patches” located around LRR12 and in 
the amino-terminal region around LRR3 [17]. Unlike the latter site, LRR12 has an 
extended LRR sequence composed of 33 residues, creating an insertion following 















that is of functional significance [13,17]. The TLR3 homodimerization interface is 
located at the carboxy-terminus around LRR20, also on the glycosylation free 
face; this region contains the densest cluster of conserved, surface exposed 
residues across species. Similarly to TLR2-associated heterodimers, surface 
exposed residues rather than internal binding cavities mediate TLR3 
homodimerization [17]. Distinct from the previously mentioned TLRs however, 
the TLR3-TLR3 interface is largely hydrophilic, stabilized mostly by ionic 
interactions and hydrogen bonds. Ionic interactions are formed between E442-
K467 and K547-D575, and further stabilization of the interface is achieved either 
through direct hydrogen bonds with the opposite TLR3 chain or through 
bridging waters. Direct intermolecular hydrogen bonds include the following: 
E442-K467, N517-N517, N541-N541, R544-N620/N596, K547-D575, N597-
N597 and N597-R544 [17]. A relatively limited number of intermolecular 
hydrophobic interactions are involved, formed via A549, P551 and L621 on 
LRR20, which like LRR12 has an extended LRR sequence with a protrusion on 
the convex portion of the carboxy-terminal region [13,17].  
 
TLR7, TLR8, and TLR9 Homodimers 
TLR7, TLR8, and TLR9 are also found in acidified endosomes, and bind nucleic 
acid fragments. Unlike other TLRs, they are synthesized as pre-formed dimers in 
the absence of an agonist. TLR7 and TLR8 bind single stranded RNA, whilst TLR9 
recognizes unmethylated CpG DNA, a form of DNA rarely found in vertebrates 
but commonly associated with viral and bacterial genomes [15,19] (Figs 1F, G). 
TLR7 and TLR8 are also activated by certain small molecules with 
immunomodulatory properties. Recent crystal structures have revealed how 
TLR8 [14] and TLR9 [19] form homodimers without the presence of ligands, 
consistent with the large buried area formed between chains. Whilst no crystal 
structure is available for TLR7, the 43% sequence identity to TLR8 suggests that 
the structure of the dimeric complex should be conserved [16,18]. Due to the 
large size of each TLR8 ectodomain (>800 residues), and its almost completely 
circular shape, the dimerization interface is very large (2,150 Å2 in the ligand 
bound form versus 1,290 Å2 in the unliganded state). Hence, unlike TLRs 1-6, 
none of whose dimerization interfaces exceed 800 Å2 in buried surface area 
(Table 1), mutation of a single residue within the TLR8 interface is unlikely to 
abrogate dimer formation, though it may affect signaling [16,18]. Likewise, the 
dimerization interface in the TLR9 homodimer is extensive (>40 residues) [19]. 
Residues involved in the TLR9 interface are found in the carboxy-terminal LRRs 
(LRR20 to LRRCT) as well as LRR18, LRR11, LRR8, LRR5 and LRR2 and are 
highly conserved across species [19], whilst ligand binding is mediated through 
surface exposed residues between LRRNT to LRR10 on the primary TLR9 chain 
and the carboxy-terminal segment LRR20 to LRR22 on the alternate TLR9.  
 
Key insights into the mechanism of signaling by TLRs were provided by the 
crystal structures of TLR8 in the liganded versus unliganded state [19] (Figs 2A, 
B). In the case of the ligand-free, preformed TLR8 dimer, the symmetric 
TLR8/TLR8 interface spans between LRR8 to LRR18 [16,18]. The interface is 
maintained by a large number of hydrogen bonds between LRR8, LRR14 to 
LRR15 and LRR18, and by a hydrophobic core consisting of F261, V378, P432, 















LRR8, LRR11 to LRR15, and LRR18 [18]. Upon binding of small molecule, 
imidazoquinoline-based ligands that bridge the chains in a hydrophobic pocket 
around LRR11 [18], the complex undergoes both local and global conformational 
changes.  
 
Local structural changes occur in the loop structures of LRR8 and LRR17 to 
LRR20, coupled with large-scale conformational changes at the TLR dimer 
interface, causing the two ectodomain chains to rotate with respect to each 
other. This results in a shift in a dimerization interface that encompasses LRR5, 
LRR8 and LRR14 to LRR20, and allows the bound ligand to form strong polar 
interactions with the highly conserved D543 on LRR17. From LRR14 to LRR20, 
additional intermolecular hydrogen bonds form between N491-R541, A514-
R541 and E427-H566 and new van der Waals contacts are formed between 
F494-F494 and S516-S516 [18]. In the peripheral region (LRR11, LRR8 and 
LRR5), extensive van der Waals contacts and hydrogen bonds further stabilize 
the new dimerization interface. Strikingly, the rearrangement of the TLR8 
complex also causes the ectodomains to tilt (Figs 2A, B), bringing their carboxy-
terminal ends into closer proximity, from ~5 nm to ~3 nm separation. It is 
speculated that this would enable the intracellular TIR domains to dimerize in 
the full-length protein, thus facilitating formation of a platform for recruitment of 
adaptor proteins to initiate downstream signaling [14-16,18].  
 
STRUCTURE AND DYNAMICS OF TLR4/MD-2 
The TLR4 signaling pathway is well studied, not least because of its importance 
in the development of anti-septic drugs and vaccine adjuvants. This is due to the 
nature of its main PAMP, lipopolysaccharide (LPS), a glycolipid from Gram-
negative bacterial outer membranes [12,47-54]. Only small amounts of LPS are 
required to stimulate the TLR4 pathway and hence alert the immune system to 
invading pathogens, and overstimulation of this pathway can lead to sepsis. 
Septic shock remains the primary killer in intensive care units, with a 30% 
mortality rate, and millions of deaths worldwide every year [6-8]. Identifying 
drugs that inhibit TLR4 complex dimerization and hence sepsis is thus of great 
interest. LPS molecules can be sub-divided into an oligosaccharide core and 
variable O antigen region, plus a hydrophobic anchor containing multiple acyl 
tails and a phosphorylated glucosamine headgroup termed lipid A [55]. Lipid A is 
the main bioactive component of LPS [12,49], but subtle variations in its 
structure can have a major impact on stimulation of the TLR4 pathway. For 
example, hexa-acylated, bi-phosphorylated lipid A from E. coli is a potent agonist 
of TLR4 in all known species, whereas its biosynthetic intermediate, tetra-
acylated lipid IVa, is an antagonist in humans (but an agonist in mice and horses) 
[56]. 
 
The TLR4 ectodomain structure resembles that of other TLR family members in 
the presence of both agonists [57] or antagonists [12,58] but its dimerization 
state is regulated in cooperation with a co-receptor protein, MD-2 (myeloid 
differentiation factor 2), to form a productive (TLR4/MD-2) 2 heterotetrameric 
complex [12] (Fig 1D). MD-2 adopts an immunoglobulin-like β-cup fold whose 
hydrophobic interior is specialized for binding lipid molecules. LPS is transferred 















(LBP) and CD14, but the binding of agonistic LPS to MD-2 is the key factor in 
determining TLR4 signaling, since MD-2 binds to the amino-terminal region of 
TLR4 and mediates active complex formation [48-53,59-61].  
 
In the heterotetrameric receptor complex, the TLR4-TLR4 interface is located in 
the carboxy-terminal portion of the proteins between LRR13 to LRR20 (Table 1). 
This region is predominantly stabilized by intermolecular hydrogen bonding 
with interactions observed between S386-N365’, S386-S386’, N433-N433’, 
Q507-Q507’, K435-N433’ and N486-Q507’, where an apostrophe corresponds to 
the second TLR4 chain [12,48,57]. The only hydrophobic contacts believed to be 
involved in stabilizing the interface in this region are symmetric V411/V411’ 
interactions, though the sidechains of F533 present on LRR22 below this 
interface are angled towards each other and may also be involved [57]. 
Interestingly, a number of histidine residues are present in and around the 
dimerization interface and are highly conserved between species (H431, H458 
and H555 at the interface, and H456 and H529 adjacent)[47]. Changes in the 
ionization state of these residues have been proposed to be the source of TLR4’s 
unique ability to activate different downstream signals at the cell surface versus 
in acidic endosomes, via pH-dependent conformational changes within the 
dimeric TLR4 complex [47]. 
 
The interactions between TLR4 and MD-2 may be broken up into two main zones 
(Fig 1D). A primary interaction site exists between the MD-2 protein and the 
concave surface of its complimentary TLR4, which is present even in the 
presence of antagonists [12,58] resulting in a buried area between TLR4 and 
MD-2 of ~800 Å2 and stabilization of the signaling-inactive TLR4/MD-2 
heterodimeric complex. The secondary interaction site, which exists only in the 
presence of agonists, is formed between the same MD-2 chain and the convex 
surface of the alternate TLR4’/MD-2’ complex [57], burying ~600 Å2 between 
the TLR4’ chain and MD-2, thus stabilizing the (TLR4/MD-2)2 heterotetramer 
(Fig 3A). At the primary interaction site, protein-protein interactions between 
MD-2 and TLR4 (with MD-2 residues quoted first) include a number of ionic 
bonds formed between R106-D209, D99-R289, R68-E42 and K109-D60/84, 
along with hydrogen bonds formed between S103-E266/N265, D101-
R264/S317, S98-R289 and D99-R289 [12,48,57]. Protein–protein interactions at 
the secondary interface between MD-2 and TLR4’ involve ionic interactions 
between K125-E422 and R90-E439, hydrogen bonds between G123-S416, K125-
N417 and R90-Q436 [48,57], along with an extensive set of ligand-dependent 
hydrophobic contacts, as discussed below.  
 
Comparison of structures in the presence and absence of an agonist reveal subtle 
conformational changes in a loop within MD-2 containing the F126 residue. In 
the LPS-bound (TLR4/MD-2)2 complex, F126 is located near to the secondary 
dimerization site but is oriented inside the MD-2 binding cavity (Fig 3A), 
interacting with L54, Y131, I124 and the bound lipid tail  [57]. In contrast, in 
agonist-free crystal structures of the TLR4/MD-2 heterodimer, this loop adopts 
different conformations in which the phenylalanine sidechain is solvent exposed 
(Fig 3B). Recently, molecular simulation approaches revealed that the β-cup fold 















similarly to other distantly related lipid-binding proteins [62], allowing it to 
adapt to the size and shape of different ligands bound within its hydrophobic 
cavity. Importantly, this dynamic adaptation was shown to be allosterically 
coupled to the F126 loop, and to determine the stability of the active receptor 
complex. Thus, in the presence of a bound agonist, F126 remains within the MD-
2 cavity (Fig 3A), enabling MD-2 residues including I80, V82, and L87 and an 
exposed lipid tail to form extensive hydrophobic contacts with TLR4’ residues at 
the secondary dimerization interface; these include F440’, L444’, and F463’, 
supported by a salt bridge between E422’ and K125 on MD-2 [48,57]. However, 
in the presence of antagonists or in the ligand-free state, F126 was observed to 
spontaneously reorient and exit the MD-2 cavity, leading to a disruption of the 
hydrophobic cluster at the secondary dimerization interface and a loss of as 
much as ~400 Å2 of buried surface area between TLR4’ and MD-2 [48,53] (Fig 
3B). Over longer timescales, it is expected that such disruption would lead to a 
loss of TLR4 dimerization and consequently separation of the TIR juxtaposition 
necessary for downstream signaling. Indeed, analysis of the dominant simulated 
motions associated with loss of agonist indicates that the carboxy-termini of the 
TLR4 ectodomains exhibit lateral fluctuations associated with chain separation 
(Fig 2C, D), not unlike the conformational changes observed in crystal structures 
of the pre-formed TLR8 dimer upon ligand unbinding (Fig 2A, B). The idea that 
F126 acts as a molecular switch to determine the key protein-protein interface 
for TLR4 dimerization is supported by mutational studies, which reveal that 
F126 and nearby residues in this loop do not prevent lipid ligand binding but 
interfere with signaling [12,48,53,57], and by NMR studies using metabolically 
labeled endotoxin which demonstrated that this loop reorients upon ligand 
binding [53].  
 
RP105 AND REGULATION OF TLR4 
RP105 (Radioprotective 105 kDa, also known as CD180) is a type I TM protein 
that shares the characteristic solenoidal LRR ectodomain structure observed in 
other TLRs. Analogous to TLR4, RP105 requires a co-receptor for dimerization 
and cell-surface expression: the MD-2-related protein MD-1 [63-65] with which 
it forms a 2:2 heterotetramer, including two copies each of RP105 and MD-1 (Fig 
4A). The shared architecture and sequence similarity between the two receptors 
(~30 % for RP105 and TLR4) suggest a common physiological role, and the 
RP105/MD-1 complex is believed to be a regulator of the LPS-induced 
TLR4/MD-2 signaling response. This receptor has been reported to fine-tune 
TLR4 pathways, and studies also suggest that it may regulate TLR2-induced 
macrophage responses to M. tuberculosis lipoproteins [66]. RP105/MD-1 
stimulation is primarily mediated and restricted to B cells, and leads to B cell 
proliferation [67,68], activation, and differentiation via a T cell-independent 
pathway [69], all of which are modulated by MyD88-dependent TLR signals [70].  
 
To date, the human, bovine, and mouse forms of RP105-MD-1 complex have been 
crystallized [71,72], and these share ~70 % sequence identity with one another. 
Unlike the typical tail-to-tail arrangement of juxtaposing carboxy-termini in 
TLRs, in all available structures the RP105 the units are arranged in a novel “m-
shaped” head-to-head fashion, placing the amino-terminal regions at the center 















domains in TLRs. However, RP105 lacks the TIR receptor domain required to 
transduce signals into the cytoplasm [21], and instead contains only an 
intracellular tail of 6-11 residues [64]. The heterotetrameric (RP105/MD-1)2 
assembly has two partially overlapping interaction interfaces. RP105 and MD-1 
form a primary interface, and then homodimerize into a 2:2 complex using a 
secondary dimerization interface, by analogy with TLR4.  
 
The primary interface in RP105/MD-1 is divided into three discontinuous 
regions corresponding to interfaces A, B, and C. Interfaces A and B involve 
protein-only contacts of the amino-terminal and central domains of RP105 and 
MD-1, and these are mostly conserved in TLR4/MD-2. On interface A, the 
conserved polar MD-1 residues form extensive contacts with RP105 residues on 
the concave side of LRRNT and LRR1 to LRR6. These include (with MD-1 
residues quoted first) the salt bridge K113-E40, and hydrogen bonds between 
R72-N41, G114-R86, R111-S158, and E115-Q134.  
 
Additionally, residues K116, G117 and E118 on MD-1 (and similarly MD-2) 
associate with F62, D83, and R86 on RP105 (and TLR4), all of which are fully 
conserved across species [71]. A small patch of hydrophobic interactions is also 
present, formed by the spatially adjacent residues K113, G114, and E115 of MD-1 
and T85, T109, T113 of RP105 [72]. Interface B is formed by residues on LRR9-
LRR13 on RP105, and eleven MD-1 ones. The major contribution here comes 
from the protruding loop of LRR9 forming three backbone hydrogen bonds on 
S107-D257 and K105-E256. The charge complementarity observed in human 
TLR4/MD-2 binding is not as pronounced in human RP105/MD-1, with only one 
salt bridge being formed, E40-K113 [72]. Overall, there are fewer protein-
protein interactions that contribute to the primary interface in human RP105 
than there are in TLR4. Nonetheless, this primary interface has a unique 
additional region C, created by an N402-linked glycan on the concave face of 
LRR15. The well-ordered glycan interacts extensively with RP105 and MD-1 
through polar interactions in the crystal structure, though expression of a non-
glycosylated bovine RP105 leads to relatively stable complexes [72], and 
molecular simulations indicate this this complex is not disrupted in the absence 
of the glycan moiety (unpublished data). 
 
The dimerization interface in RP105 is made up of two regions: an RP105’/MD-1 
(α) interface and an RP105/RP105’ (β) one, where an apostrophe corresponds 
to the second RP105 chain. Interface α is made up of 19 hydrophobic residues 
from RP105 (W91, I114, F115, F142, highly conserved in all species) that are 
stacked against a flat face of beta sheets on MD-1 (G49, G68). Nearby polar 
interactions support the hydrophobic regions (with MD-1 residues quoted first), 
including: R66-E141, T28-E94, and Q116- S138, and some pi-stacking between 
F142-Y118. The smaller dimerization interface β is symmetric and hydrophobic 
with interactions between H186-H186’, and a polar pairing between S162-K212’. 
 
Despite some controversy on its reported cell-dependent dichotomous effect on 
TLR4 signaling, it is thought that in antigen-presenting cells the RP105 complex 
down-regulates LPS responses by direct interaction with TLR4, preventing 















achieved as a result of the MD-1 bound RP105 carboxy-terminal region replacing 
the equivalent homodimerization interface of the TLR4/MD-2 receptor complex 
[71,72] (Fig 4B). This would involve polar interactions between residues R431, 
H433, E383 of RP105 and K453, R460, Q436 and E439 of TRL4 without any 
major structural reconfiguration. Whilst this is an attractive model for the 
apparent inhibitory behavior of the LPS-induced TLR4 response by RP105, 
confirmation awaits high-resolution structural data of the complete inhibitory 
complex. 
 
TLR TRANSMEMBRANE DOMAINS 
The TM domains (TMDs) of many membrane proteins are associated with their 
activation, assembly and regulation [75-77]. The functional significance of TMDs 
and their mechanisms of assembly have previously been demonstrated for many 
membrane proteins including integrins, receptor tyrosine kinases and G-protein 
coupled receptors [78-80]. Several biochemical studies have emphasized the 
functional relevance of TMD interactions and their regulation [81-84] in the TLR 
family. Recently, the ToxR assay was used within E. coli membranes to study the 
intrinsic capacity for homo- and hetero-dimerization of the isolated TMDs from 
all human TLRs [75]. The TLR TMD segments were thus expressed as a chimeric 
protein, fused to an extracellular maltose-binding protein that orients the 
construct to the periplasm, along with a cytoplasmic cholera toxin 
transcriptional activation domain (ToxR). Upon TMD oligomerization, the 
dimeric ToxR domains bind to their promoter, leading to expression of the β-
galactosidase reporter [85-87]. All human TLR TMD constructs exhibited strong 
homotypic interactions, whilst TLR2 formed stable heterodimers only with their 
associated subfamily members, TLR1, TLR6 and TLR10 [75], consistent with 
their biologically relevant roles in ligand recognition discussed above, and with 
their high sequence identities of ~50-90%. Further biochemical and biophysical 
assays showed that exogenous synthetic peptides of mouse TLR2 and TLR6 
TMDs, expressed in macrophages, affect TLR2 activation by inhibiting TNF-α 
secretion upon stimulation by lipoteichoic acid, a TLR2/6 activator from Gram-
positive bacteria [5]. These studies confirmed heterodimerization and strong 
associated heterotypic interactions between the TLR2 and TLR6 TMDs. 
Moreover, in vivo studies have demonstrated the potential for therapeutic 
targeting by TMDs, by showing that these peptide constructs could inhibit TLR2 
activation, reducing lethal inflammation in mice [5].  
 
As pointed out by Shai and co-workers [22], several amino acid motifs known to 
be involved in self-assembly and stability of other TM helix-helix interactions are 
present in the TLR TMDs, such as Small-xxx-Small (TLR2/7/9/10), aromatic-xx-
aromatic (TLR5/8), and polar-xx-polar (TLR1/5/6) motifs, along with the 
general presence of multiple TM polar residues that may place a possible 
functional role in membrane assembly and transmembrane receptor function. A 
recent solution NMR spectroscopy study revealed the conformations of both 
dimeric and trimeric assemblies of the TLR3 TMDs in dodecyl-phosphocholine 
(DPC) detergent micelle environments, providing the first atomic-resolution 
structural information for the oligomerization of TLR TMDs [88]. Both the 
homodimer and homotrimer were shown to adopt α-helical conformations 















for other members of the TLR family [5,75]. In the dimeric conformation, the 
protein-protein interaction interface involved symmetrical contacts between 
residues F706, T710, L714 and F718 [88] (Fig 5A). The aromatic rings of F706 
and F718 in particular make van-der-Waals contacts across the interface with 
the potential for stacking interactions. In the case of the trimeric structure, two 
distinct contact surfaces could be identified in addition to the symmetrical 
dimerization interface, including F705, N709, L713 and I717 on one side of the 
TM helix, and I708, I712 and F716 on the other [88]. Whilst the biological 
relevance of the trimer may be questionable, since there is no evidence for such 
functional oligomerization in TLRs, the observed contact surfaces are in 
agreement with a model for the full-length TLR3 receptor in the active state 
proposed by Davies and co-workers [89], suggesting that there may be multiple 
TM interfaces associated with different functional states of the TLR3 receptors. 
The oligomers and associated TM helix-helix interactions were observed to be 
more stable at low pH, possibly due to intermolecular H724-E726 contacts 
between the helices [90]. The dimerization and trimerization free energies 
measured for TLR3 [88] were slightly more stable than those of other TM 
domains such as ErbB3 [91] and ErbB4 [92], but much weaker than the 
archetypal transmembrane homodimer, glycophorin A (GpA), whose TMD 
contains the GXXXG motif [93,94]. 
 
Whilst the NMR structure provides important structural insights into the 
assembly of the TLR3 TMDs within detergent micelles, the high-resolution 
interaction mode of these helices within phospholipid bilayers remains 
undefined. This is important, since solution and solid-state NMR studies of the 
GpA TMDs revealed homodimeric structures within both detergent micelles and 
lipid membrane environments respectively, but an altered crossing angle and 
difference in interfacial packing arrangement was observed [95,96]. A molecular 
simulation approach may be taken to help resolve these differences. As 
demonstrated using both atomically-detailed [97] and simplified, coarse-grained 
simulations [98] of GpA, different converged TM dimeric structures result 
depending upon the local environment. Thus, a significant relative rotation and 
crossing angle of the two helices was observed when comparing GpA dynamics 
within detergent micelles versus phospholipid bilayers, and the TMDs were 
observed to sample a significantly larger range of crossing angles in the micelle 
environment [97]. By analogy, similar simulation studies have been undertaken 
for the TLR3 TM homodimer within a palmitoyl-oleyl-phosphatidylcholine 
(POPC) lipid bilayer (unpublished data), based on the dimeric NMR structure 
(Fig 5B). Preliminary results from 200 ns all-atom simulations [88] revealed a 
significantly smaller crossing angle (~30o) between the helices compared to the 
NMR structure (~60 o), and a consistent switch in the interaction interface (Fig 
5C). Thus, the sidechains of the weakly interacting F706 as well as those of T710, 
which do not take part in polar intermolecular contacts in the NMR structure but 
instead form intramolecular hydrogen-bonds [88], were observed to rotate away 
from the interaction interface. This was compensated by improved 
intermolecular stacking interactions between F718 and van-der-Waals contacts 
between L722, maintaining a favorable buried surface area at the protein-
protein oligomerization surface and an optimized transmembrane configuration 















similar principles apply to other TMD members of the TLR family awaits further 
structural and computational studies.  
 
DOMAINS ASSOCIATED WITH DOWNSTREAM SIGNALING 
TIR domains brought together by dimerization act as scaffolds for downstream 
adaptor proteins for subsequent propagation of signal cascades [5]. Adaptor 
proteins also contain TIR domains and associate with receptor dimers through 
TIR/TIR interactions. TIR domain containing proteins include not only receptors 
but also signaling-adaptor proteins. Heterotypic TIR-TIR interactions between 
receptors and adaptors thus enable formation of higher-order complexes, which 
eventually lead to activation of key transcription factors and production of 
cytokines [21,99]. Thus, the MAL (or TIRAP) adaptor bridges MyD88 to receptor 
TIR domains, whilst TRAM likewise bridges TRIF to receptors, to facilitate 
alternate downstream signaling pathways. The MyD88 pathway is associated 
with all TLRs except TLR3, which uses TRIF alone, whilst TLR2 and TLR4 can 
signal through both MyD88 and TRIF. 
 
A number of crystallographic structures are available for both receptor and 
adaptor TIR domains, providing useful information concerning potential 
interaction interfaces and rationalizing conservation patterns and/or mutations 
that affect TIR domain functionality [100-102]. Unfortunately, there is presently 
limited high-resolution information on the homotypic and heterotypic 
interactions required for the binding of adaptor TIRs to those of the TLRs. This 
may be because isolated TIR domains do not form stable multimers when 
detached from their full-length construct [102], whilst TIR-TIR domain 
interactions appear to be weak and transient, suggesting stable dimerization 
may only occur in the larger context of multivalent macromolecular complexes 
[99].  
 
Structures of TIR domains from TLR1, TLR2, TLR6, TLR10, MyD88, and MAL 
indicate that all share a common α/β architecture comprising four or five 
parallel β-strands (βA-βE) surrounded by five α-helices (αA-αD) [102]. Early 
crystal structures of isolated TLR1 and TLR2 TIR domains revealed a large 
conserved surface patch crucial for receptor signaling, which contains a key 
region, the BB loop (which connects the αB-helix with the βB-strand) exposed on 
the surface. Mutation of a proline residue (P681 in TLR2) to histidine within the 
BB loop that is conserved across most mammalian TLRs (except TLR3) disrupts 
signal transduction [102-105], indicating that the conserved patch mediates 
interactions with downstream adaptor molecules. The importance of the BB loop 
in dimerization is supported by several crystallographic studies of TLR TIR 
domains [100,101,106], and by BB loop peptide decoys which inhibit TLR 
signalling [107], paving the way for the design of specific antagonists against 
certain downstream TLR pathways [108] [109]. In addition to the BB loop, the 
DD loop (connecting the αD helix to the βD strand) has been shown to be 
important for signaling, and may mediate heterotypic interactions with the BB 
loop on partner TIR domains [24]. 
 
In contrast to TLR2 [110], structures of TLR6 [100] and TLR10 [101] TIR 















TLR6, the dimeric interface was formed via mutual interactions between the CD 
loop, DD loop, and αC helix, whereas for TLR10, this interface was formed mainly 
by the αC helices plus BB loops. It is thus possible that there is no single 
universal dimerization interface for TIR-TIR interactions, and it is also important 
to note that the length and conformation of loops across the TIR domain family 
vary significantly. Nevertheless, models for heterotypic TIR signalling complexes 
have been proposed on the basis of the various available crystallographic and 
biochemical data. One notable study combined information from the X-ray 
structure of homodimeric TLR10 TIR [101] with protein docking to model the 
receptor-adaptor TIR complex for TLR4. This placed the BB loop forming 
homotypic interactions between receptor TIR domains, with the TIR domains of 
TRAM and MAL binding to two symmetrical sites formed by the TLR TIR dimer, 
and was supported by extensive mutagenesis studies, phosphorylation site 
analysis, and peptide inhibition mapping [106]. In contrast, on the basis of a 
crystallographic structure of a homodimeric bacterial TIR domain which 
interferes with MyD88 function, its BB loop was proposed to play a role not in 
homotypic TIR interactions but in heterotypic interactions with MyD88, further 
highlighting the diversity of possible protein-protein interfaces associated with 
TIR domain assemblies. 
 
Finally, it should be noted that a significant body of recent evidence indicates 
that the engagement of adaptor proteins with the TIR domains of TLRs results in 
the assembly of extensive higher-order macromolecular complexes that promote 
downstream immune responses, and may be important in TLR-dependent 
clustering and signal amplification [99]. The best characterized one, termed the 
“Myddosome”, results in MyD88-dependent activation of NF-κB activation [108]. 
By analogy, oligomeric TRIF-based complexes (“Triffosome”) are also known to 
exist, though their structural characterization is less far advanced [21]. MyD88 
contains two signalling domains, an amino-terminal TIR domain, and a carboxy-
terminal death domain which can recruit IL-1R-associated kinase (IRAK) 
proteins via their own death domains, thus stimulating kinase activity. The 
crystal structure of a complex formed by the death domains of MyD88, IRAK4, 
and IRAK2 [111] provided insights into at least one form of the Myddosome. The 
large complex consisted of a helical, three-layered arrangement of six MyD88, 
four IRAK-4, and four IRAK-2 death domains. This layered arrangement is 
suggestive of the sequential process of recruitment that may enable positive 
cooperativity in signalling. This complex may be important in higher-order 
clustering of TLRs by interacting with additional TLR dimers, and there is 
evidence that the Myddosome complex stoichiometry varies in vivo, which may 
result in differential signalling outputs [21]. 
 
CONCLUSIONS 
A large body of high-resolution crystallographic data is now available for the 
ectodomains of homo- and heterodimeric TLR and TLR-like complexes, 
highlighting general themes and key differences across the family. Moreover, 
recent structural information, supported by a wealth of biochemical and 
simulation data, has provided insights into the mechanisms by which these 
ectodomains and associated co-receptor proteins propagate allosteric signals 















productive receptor complexes. Furthermore, recent structural data combined 
with computational modeling have provided new insights into the possible 
protein-protein interactions involved in TLR transmembrane assembly and TIR-
mediated signaling complex formation. Nevertheless, our understanding of TLR 
function would benefit from further structural information concerning modes of 
interaction and oligomerization, particularly in the context of the 
physiologically-relevant environment. For example, the stability of several TLR 
complexes and their interaction with ligands are dependent upon local pH, 
whilst the lipid membrane in which TLRs are embedded are likely to influence 
both TM structure/dynamics and the interaction with membrane proximal 
adaptor proteins and associated complexes. Likewise, higher-order 
macromolecular assembly beyond the TLR dimer may be relevant in a biological 
setting, and combined with receptor clustering (possibly in a lipid raft dependent 
manner) [99], likely plays a key role in determining receptor cooperativity and 
hence the cellular signalling output. Further structural, biochemical, and 
computational studies should continue to uncover new insights into the 
interplay between the different TLR components, and ultimately drive the 
















































Table 1. Structural and functional properties of ligand-bound TLR dimers. 
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Figure 1. Crystal structures of TLR ectodomains with both ligands. 
Structures are shown for: (A) the TLR1-2 heterodimer in complex with 
Pam3CSK4 (PDB:2Z7X); (B) the TLR2-TLR6 heterodimer in complex with 
Pam2CSK4 (PDB:3A79); (C) the TLR3 homodimer in complex with dsRNA 
(PDB:3CIY); (D) the TLR4/MD-2 heterotetramer in complex with LPS 
(PDB:3FXI); (E) the TLR5 homodimer in complex with flagellin (PDB:3V47); (F) 
the TLR8 homodimer in complex with a nucleoside (PDB:4QBZ); and (G) the 
TLR9 homodimer in complex with ssDNA (PDB:3WPC). The individual TLR 
chains in each dimer are shown as blue and yellow cartoons, with ligand in green 
wireframe format. Bound MD-2 co-receptor for TLR4 is shown in red cartoons 
format. The carboxy-termini are indicated by labels (CT) in each TLR ectodomain 
structure. 
 
Figure 2. Conformational changes in the carboxy-terminal regions of TLR 
ectodomains, which may be related to downstream signaling. Crystal 
structures are shown for TLR8 in (A) the ligand-bound state (PDB:4QBZ) and 
(B) the ligand-free state (PDB:3W3G). In (C), the TLR4 ectodomain dimer from 
the crystal structure of the TLR4/MD-2 complex bound to LPS ligand (PDB:3FXI) 
is shown, and compared with (D) porcupine plot representing simulated 
dominant motions of the TLR4 ectodomain dimer, with magnitudes of atomic 
motion indicated by length and color of associated arrows. In the TLR8 crystal 
structures, the ectodomain chains are represented as cartoons, with the ligand in 
red wireframe format. For clarity, only the ectodomain chains are shown for the 
TLR4 crystal structure, in cartoons format. The porcupine plot is based on 
molecular dynamics simulations of TLR4 in the absence of bound ligand (48), 
derived from principal components analysis of the trajectory. 
 
Figure 3. The molecular switch in TLR4 signaling. Snapshots derived from 
molecular dynamics simulations (48), are shown for the TLR4/MD-2 
heterotetrameric complex in (A) the presence of bound lipid A, and (B) the 
ligand-free, apo state. The two TLR4 chains are shown as blue and yellow 
cartoons, with an MD-2 co-receptor in red cartoons format, and bound ligand is 
shown in green wireframe representation. The key Phe126 residue that switches 
between the ligand-bound and free states, thus influencing the stability of the 
complex, is shown in CPK spacefill format.  
 
Figure 4. The RP105/MD-1 complex that inhibits TRL4 function. In (A) the 
crystal structure of RP105 (PDB:3RG1) in the heterotetrameric (RP105/MD-1)2 
complex is shown. In (B) a hypothetical inhibitory model of the RP105/TLR4 
complex is shown, modeled using PDB structures 3B2D (RP105) and 3FXI 
(TLR4), and based on work by Yoon et al (72). The carboxy-termini are indicated 
by labels (CT) for each RP105 and TLR ectodomain structure. Each protein chain 
is shown in cartoons format, with ligand (TLR4) or oligosaccharide (RP105) 
colored in green wireframe format. RP105 chains are shown in cyan and grey, 

















Figure 5: The structure and dynamics of transmembrane TLR3 domains. In 
(A) the structure of the lowest-energy solution NMR model of the TM domain of 
dimeric TLR3 within DPC micelles is shown. This was used to setup a molecular 
dynamics simulation system, shown in (B), containing the TLR3 transmembrane 
dimer, rotated by 90° about its axis compared to (A), embedded within a POPC 
lipid bilayer and solvated by a physiological salt solution. In (C), the final, 
equilibrated structure from this simulation is shown, from the same perspective 
as (A). The transmembrane helices are shown as cartoons, with sidechains key to 
stability of the dimeric interface represented in wireframe format and labelled. 
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